ezetimibe + rosuvastatin + telmisartan

Ezetimibe + rosuvastatin + telmisartan is a fixed-dose combination therapy used primarily for patients with both dyslipidemia and hypertension. Ezetimibe acts as a cholesterol absorption inhibitor, reducing cholesterol transport from the small intestine to the liver by preventing its absorption in the gut. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers LDL cholesterol by inhibiting endogenous cholesterol synthesis in the liver. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking angiotensin II type 1 receptors, leading to vasodilation and reduced aldosterone secretion. The combination targets both elevated blood pressure and high LDL-C levels, providing complementary mechanisms for cardiovascular risk reduction[1][3][8]. This triple therapy has been shown to be effective and safe compared to dual or monotherapy regimens in clinical studies involving patients with coexisting hypertension and dyslipidemia[1][5][8].

Brand names

Duowell-ATelmimet PlusTri-VTelrosu-E

Other names

TRE